(DNTH)

Role: CEO AND PRESIDENT, Director
Signature: /s/ Adam Veness, as attorney-in-fact for Marino Garcia
Issuer symbol: DNTH
Transactions as of: 12 Mar 2026
Net transactions value: -$10,016,381
Form type: 4
Filing time: 13 Mar 2026, 20:30:07 UTC
Previous filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Garcia Marino	CEO AND PRESIDENT, Director	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK	/s/ Adam Veness, as attorney-in-fact for Marino Garcia	13 Mar 2026	0001669866

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNTH	Common Stock	Options Exercise		+122,918		$6.70^*	122,918	12 Mar 2026	Direct	F1
transaction	DNTH	Common Stock	Sale	$3,510,418	-43,505	-35%	$80.69	79,413	12 Mar 2026	Direct	F1, F2
transaction	DNTH	Common Stock	Sale	$5,355,360	-65,517	-83%	$81.74	13,896	12 Mar 2026	Direct	F1, F3
transaction	DNTH	Common Stock	Sale	$1,056,950	-12,796	-92%	$82.60	1,100	12 Mar 2026	Direct	F1, F4
transaction	DNTH	Common Stock	Sale	$16,676	-200	-18%	$83.38	900	12 Mar 2026	Direct	F1
transaction	DNTH	Common Stock	Sale	$76,977	-900	-100%	$85.53	0	12 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise		-122,918	-67%	$0.000000^*	59,741	12 Mar 2026	Common Stock	122,918	$6.70	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025.
F2	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.29 to $81.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.29 to $82.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.29 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.